Transcell Biologics, a biotech company has raised an undisclosed amount of investment from Boston-based IAN Group and Quantiphi.
The proceeds will be allocated to the expansion of the client base and the implementation of Digital Animal Replacement Technology (DART) as an enterprise solution for the global bio and pharmaceutical industry.
DART offers animal-free testing methods that integrate human MicroPhysiological Systems (hMPS) technology with AI/ML embedded in silico platform configurations to automate and expedite the bioassay processes, resulting in statistically compliant reports. The solution is intended to efficiently evaluate the safety and efficacy of medications and vaccines intended for human consumption.
According to Transcell Biologics, the implementation of DART has acquired substantial momentum in Indian markets, as biopharmaceutical companies have incorporated its enterprise solution into their high-impact programs. Transcell Biologics intends to broaden its clientele in Japan, Europe, and the United States.
“DART represents a significant breakthrough in revolutionising drug and vaccine testing. This innovative approach offers a decentralised strategy without additional infrastructure requirements at end users’ premises, enhancing the operating efficiency and accessibility of such validated testing procedures from their workstations,” said Subhadra Dravida, the Founder and CEO of Transcell Biologics.
Transcell Biologics, which was established in 2009 by Subadra Dravida, is a company that specializes in the optimization of stem cell yield while maintaining pluripotency and functionality. The company has also diversified its applications for stem cell technologies and offers a proprietary process.
